Sequential Bortezomib Plus Temozolomide is Safe, Effective for Recurrent Glioblastoma
Dorota Goplen, MD, Haukeland University Hospital, Bergen, Norway, discusses results from a phase 1b/2 single arm, multicenter study (BORTEM-17) evaluating the efficacy of sequential treatment with bortezomib and temozolomide for patients with glioblastoma and unmetylated MGMT promoter.
Preliminary data from BORTEM-17 showed that this regimen is safe and effective and may offer an additional line of treatment for this patient population, particularly those with otherwise poor prognosis.
Dr Goplen presented these findings at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
Source:
Goplen D, Rahman MA, Brandal P, et al. BORTEM-17: A phase IB/II single arm, multicentre study investigating the efficacy of sequential bortezomib and temozolomide in recurrent GBM with unmethylated MGMT promoter—The results of an interim analysis. Presented at 2023 ASCO Annual Meeting; June 2-6, 2023; Chicago, IL. Abstract 2019
